BrainMap

Mrs. Mia Camelia Hotnog

PhD

Researcher - INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU"

Researcher

Web of Science ResearcherID: ABD-5954-2020

Curriculum Vitae (09/10/2019)

Expertise & keywords

Development of anticancer nanoparticulate systems based on novel metal complexes Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2019-5143 2020 - 2022

Role in this project:

Coordinating institution: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU"

Project partners: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO); UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO)

Project website: https://www.virology.ro/ro/cercetare/proiecte/proiect-ped-383-2020

Abstract:

A new generation of efficient metal-based drugs needs to be developed in order to overcome the biological, biopharmaceutical and biomedical drawbacks of standard chemotherapy. Use of metallo-drugs in cancer treatment has been hampered by an indaquate pharmacokinetic profile that limited the access to the biological target. This has led to the development of novel technologies based on nanostructured materials, acting as vectors for metallodrug delivery or simply as protectors of active species of the complexes for amplifying their activities and reducing their degradation. The aim of the project is to develop and validate new liposomal systems for transport and delivery of 2 promising anticancer agents previously studied by our research group. Nanoparticulate drug carrier systems will improve the therapeutic effectiveness and safety profile of these novel anticancer agents. The efficiency of these nanoformulations will be evaluated in terms of stability, drug entrapment efficiency, release behaviour, cell uptake, cytotoxicity, farmacotoxicology and pharmacokinetics. The project specific objectives are: 1) Development of liposomal systems validated at the laboratory level with novel anticancer agents; 2) Estimation the in vitro biological activity of the liposomal systems on various cell lines, including drug resistant cell lines, identifying biomarkers involved in modulating their biological activity; 3) Estimating the pharmaco-toxicological and pharmacokinetic profile of liposomal systems. Nanoparticles provide an enhanced bioavailability, in vivo stability, intestinal permeability, solubility, sustained and targeted delivery, therapeutic effectiveness of the anticancer drugs. The proposed project is a complex, interdisciplinary study related to biomedical international research, that aims to intends to transform modern methods, worldwide used in pharmacological, immunological and molecular biology studies, in instruments used for the translation to oncology.

Design and development of transport and delivery systems for new ruthenium compunds with antitumor activity Call name: Joint Applied Research Projects - PCCA-2011 call, Type 2
PN-II-PT-PCCA-2011-3.2-1454 2012 - 2016

Role in this project:

Coordinating institution: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA

Project partners: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); INSTITUTUL ONCOLOGIC PROF.DR.ALEXANDRU TRESTIOREANU BUCURESTI (RO); UNIVERSITATEA BUCURESTI (RO); INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO); PHARMA SERV INTERNATIONAL SRL (RO)

Affiliation: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO)

Project website: http://cercetare-umf.ro/uploads_ro/592/Pagina_web_136_2012-actualizata_2016.pdf

Abstract:

The proposed cooperative study is a complex interdisciplinary approach aimed at developing pharmaceutical product models with significant antitumor action and minimal side effects. During the project, three pharmaceutical systems that include some ruthenium complexes will be studied regarding solubility, capacity to transport and deliver the active substance at the final site of action, the antitumor activity and the side effects. The final scope of the project is to select the system (or systems) who best meet the requirements regarding bioavailability and pharmaco-toxicological properties for a possible inclusion in the clinical trials of the studied ruthenium complexes.

The proposed project has least three main goals. First, we want to develop pharmaceutical systems for improve the solubility of some ruthenium compounds in order to achieve a better pharmacokinetic profile for these compounds. Second, we intend to evaluate the antitumor activity of the developed systems using various cell lines from solid tumors and in vivo, comparing to cisplatin as reference substance. Third, we intend to evaluate the general toxicity of the developed systems, comparing to cisplatin. Additionally, we want to explore the possibility of development of these products as oral drugs and to establish what kind of cancer can be treated with these agents.

FILE DESCRIPTION	DOCUMENT
List of research grants as project coordinator or partner team leader
Significant R&D projects for enterprises, as project manager
R&D activities in enterprises
Peer-review activity for international programs/projects